What the Research Found
A new analysis published in Psychiatric Times is putting hard numbers behind something many ketamine patients already know intuitively: how a medication feels during treatment matters as much as whether it works. The piece, released April 22, 2026, examines side effect profiles and discontinuation rates across NMDA receptor antagonists — the drug class that includes ketamine, esketamine (Spravato), and related compounds — in patients with treatment-resistant depression (TRD).
The core clinical message is pointed: clinicians are being urged to move faster and smarter. That means optimizing doses earlier, switching treatment modalities sooner when response is inadequate, and leaning on structured outcome tracking — specifically PHQ-9 scores and documented side effect logs — to reach remission more efficiently rather than waiting out ineffective regimens for weeks or months.
The analysis reinforces that NMDA antagonists as a class carry a distinctive tolerability profile compared to traditional antidepressants. Dissociation, dizziness, nausea, elevated blood pressure, and perceptual disturbances are consistently reported across delivery formats, but their frequency, intensity, and duration vary meaningfully depending on how the drug is administered — intravenous infusion, intranasal spray, or sublingual troche.
Why This Matters Specifically for Troche Users
For patients using ketamine troches at home, this research lands differently than it does for someone receiving clinic-based IV infusions. Troche treatment is largely self-managed, which means the burden of monitoring side effects and assessing response falls more directly on the patient — and their prescribing clinician's ability to adjust quickly depends on how reliably that information gets communicated.
The discontinuation rate data is particularly relevant here. Patients stop NMDA treatments for two broad reasons: insufficient efficacy or intolerable side effects. Troches occupy a unique middle ground in this picture. Because sublingual ketamine produces a more gradual absorption curve than IV infusion — peak plasma levels are lower and the dissociative experience is generally milder — many patients who found IV sessions too intense actually tolerate troches well. That lower peak-concentration profile translates directly into a softer side effect ceiling for most users.
However, troches also introduce variables that clinic settings control more tightly: the timing of the dose relative to meals, whether the troche is fully dissolved before swallowing, ambient setting, and consistency of the set-and-setting environment. These factors influence both how the medication feels and how well it works. A patient experiencing persistent nausea or anxiety with their troche may be encountering an avoidable administration variable rather than a true drug intolerance — a distinction that matters enormously when clinicians are deciding whether to adjust dose, modify timing, or switch delivery formats entirely.
The call for faster dose optimization is also directly actionable for troche patients. Standard troche protocols often start conservatively — 100–200mg sublingually — and titrate upward over several sessions. The new data supports being more deliberate about that titration timeline: if three to four sessions at a given dose haven't moved PHQ-9 scores meaningfully, that's a signal to escalate or reassess rather than continue at the same level indefinitely.
Key Takeaway for Troche Patients
Don't wait passively through a plateau. If your PHQ-9 scores aren't improving after several troche sessions at the same dose, that's clinically meaningful data — not a reason to stay the course. Document your side effects after each session and bring that log to your provider. The research now supports faster adjustments, and your notes are what make those adjustments possible. A tolerability issue with troches may also reflect how you're taking them, not just what you're taking.
Troches vs. Infusions vs. Nasal: The Tolerability Comparison
The Psychiatric Times analysis covers NMDA antagonists broadly, but the tolerability differences between delivery formats are worth unpacking for anyone choosing between options or considering a switch.
IV ketamine infusions produce the most intense and immediate experience — plasma levels peak sharply, which is why dissociation and cardiovascular effects are most pronounced in this format. For patients with severe TRD who haven't responded to other treatments, that intensity may be clinically necessary. But it also drives higher rates of session-level distress and, in some cases, discontinuation.
Esketamine nasal spray (Spravato) is FDA-approved and delivered in a controlled clinical setting, which provides oversight but limits flexibility. Its side effect profile overlaps substantially with IV ketamine — dissociation, dizziness, and nausea are common — and the twice-weekly induction schedule can be logistically demanding.
Troches sit in a practical middle lane. The sublingual route produces meaningful antidepressant effects at doses that most patients find manageable, often without the full dissociative intensity of infusions. For patients who are earlier in their TRD journey, who have had difficulty tolerating clinic-based formats, or who need a maintenance protocol they can sustain over months, troches offer a tolerability and convenience profile that infusions simply can't match.
The tradeoff is that troche protocols are less standardized, more dependent on patient self-management, and the evidence base — while growing — remains thinner than for IV or nasal formats. That's exactly why the call to track PHQ-9 and side effects systematically is so relevant: in the absence of a clinic-controlled setting, structured self-monitoring is what closes the gap.
Practical Steps Worth Taking Now
If you're currently on a troche protocol, the research-backed adjustments are straightforward. First, start logging your PHQ-9 score before each session cycle — bi-weekly or monthly works for most maintenance patients. Second, keep a brief side effect note after each session: what you experienced, how long it lasted, and whether it felt different from prior sessions. Third, if you've been at the same dose for six or more sessions without a clear response signal, bring that data to your prescriber explicitly rather than assuming the protocol just needs more time.
For patients weighing troches against other formats, the discontinuation data reinforces that tolerability is a legitimate clinical consideration — not a secondary concern. A treatment you can actually sustain is more valuable than one that's theoretically more potent but that you stop after three sessions.
Read the full analysis at Psychiatric Times.
Share